Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

166
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
166
Vaccine Production01:23

Vaccine Production

57
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
57
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

466
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
Cross-reactivity00:42

Cross-reactivity

33.8K
Overview
33.8K
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

2.0K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
2.0K
Hybridoma Technology01:31

Hybridoma Technology

18.5K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Wilderness Medical Society Clinical Practice Guidelines for the Treatment of Pit Viper Envenomations in the United States and Canada: 2026 Update.

Wilderness & environmental medicine·2026
Same author

Fatality Following Gila Monster Envenomation.

Wilderness & environmental medicine·2026
Same author

Atypical Severe Bupropion and Olanzapine Toxicity with Delayed Cardiac Decompensation and Transient Tachycardia Requiring Extracorporeal Membrane Oxygenation.

The Journal of emergency medicine·2025
Same author

Once, twice, three times a bite victim: recidivism in snake envenomation.

Clinical toxicology (Philadelphia, Pa.)·2025
Same author

Total CroFab and Anavip Antivenom Vial Administration in US Rattlesnake Envenomations: 2019-2021.

Journal of medical toxicology : official journal of the American College of Medical Toxicology·2023
Same author

ACMT Position Statement: Allow Optimal Treatment for Healthcare Professionals with Opioid Use Disorder.

Journal of medical toxicology : official journal of the American College of Medical Toxicology·2021

Related Experiment Video

Updated: Apr 2, 2026

Author Spotlight: Optimizing Scorpion Venom Extraction for Antivenom Production
05:27

Author Spotlight: Optimizing Scorpion Venom Extraction for Antivenom Production

Published on: October 6, 2023

4.6K

Antivenom Therapy: History, Production, and Emerging Innovations.

Nicklaus Brandehoff1, Meghan Spyres2

  • 1Department of Emergency Medicine, Division of Medical Toxicology, University of Colorado School of Medicine, Aurora, CO.

Wilderness & Environmental Medicine
|April 1, 2026
PubMed
Summary

Snakebite envenomation is a major health issue. New antivenom therapies, including recombinant antibodies and small-molecule inhibitors, offer improved efficacy, safety, and accessibility for treating venomous snakebites globally.

Keywords:
antivenomenvenomationsmall molecule therapeuticstoxinology

More Related Videos

High Throughput Quantitative Expression Screening and Purification Applied to Recombinant Disulfide-rich Venom Proteins Produced in E. coli
12:16

High Throughput Quantitative Expression Screening and Purification Applied to Recombinant Disulfide-rich Venom Proteins Produced in E. coli

Published on: July 30, 2014

25.0K
Extraction of Venom and Venom Gland Microdissections from Spiders for Proteomic and Transcriptomic Analyses
10:25

Extraction of Venom and Venom Gland Microdissections from Spiders for Proteomic and Transcriptomic Analyses

Published on: November 3, 2014

34.9K

Related Experiment Videos

Last Updated: Apr 2, 2026

Author Spotlight: Optimizing Scorpion Venom Extraction for Antivenom Production
05:27

Author Spotlight: Optimizing Scorpion Venom Extraction for Antivenom Production

Published on: October 6, 2023

4.6K
High Throughput Quantitative Expression Screening and Purification Applied to Recombinant Disulfide-rich Venom Proteins Produced in E. coli
12:16

High Throughput Quantitative Expression Screening and Purification Applied to Recombinant Disulfide-rich Venom Proteins Produced in E. coli

Published on: July 30, 2014

25.0K
Extraction of Venom and Venom Gland Microdissections from Spiders for Proteomic and Transcriptomic Analyses
10:25

Extraction of Venom and Venom Gland Microdissections from Spiders for Proteomic and Transcriptomic Analyses

Published on: November 3, 2014

34.9K

Area of Science:

  • Toxicology and Pharmacology
  • Immunology and Biotechnology

Background:

  • Snakebite envenomation presents a significant global health challenge, causing widespread morbidity and mortality, particularly in resource-limited areas.
  • Traditional antivenom production, relying on animal-derived polyclonal antibodies, has seen limited innovation over the past century, facing challenges in availability, cost, and safety.

Purpose of the Study:

  • To review the current state of antivenom therapy for snakebite envenomation.
  • To explore emerging therapeutic strategies and innovations aimed at overcoming the limitations of traditional antivenoms.

Main Methods:

  • Review of recent research and advancements in antivenom development.
  • Analysis of novel approaches including small-molecule inhibitors, monoclonal antibodies, recombinant antibodies, and immunoglobulin Y-based therapeutics.
  • Evaluation of the potential of these new agents to improve precision, scalability, safety, and cost-effectiveness.

Main Results:

  • Traditional antivenom production methods remain largely unchanged, leading to persistent challenges.
  • Emerging therapies like varespladib and marimastat show promise as targeted adjuncts.
  • Recombinant and engineered antibodies offer potential for safer, more consistent, and cost-effective antivenom solutions.

Conclusions:

  • Innovations in antivenom development are crucial for addressing the global burden of snakebite envenomation.
  • While promising, no single new approach currently solves all challenges, necessitating continued research and multidisciplinary collaboration.
  • Future efforts should focus on developing effective, accessible, and equitable snakebite treatments worldwide.